Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,680 SEK | +0.27% | +2.78% | +24.09% |
05:26am | AstraZeneca Pledges $388 Million Investment at French Site | MT |
May. 12 | Pfizer and AstraZeneca announce new investments of nearly $1 billion in France | RE |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The firm trades with high earnings multiples: 22.58 times its 2024 earnings per share.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+24.09% | 240B | - | ||
+30.38% | 684B | C+ | ||
+26.51% | 568B | B | ||
-4.36% | 361B | C+ | ||
+19.30% | 329B | B- | ||
+3.73% | 284B | C+ | ||
+8.78% | 208B | B- | ||
-7.93% | 200B | A+ | ||
+7.68% | 166B | C+ | ||
-2.71% | 159B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AZN Stock
- AZN Stock
- Ratings AstraZeneca PLC